Get the Stockscreener App
5.10
0.78%
-0.04
After Hours:
1.90
-3.20
-62.75%
Exicure Inc stock is traded at $5.10, with a volume of 33,281.
It is down -0.78% in the last 24 hours and up +31.61% over the past month.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
See More
Previous Close:
$5.14
Open:
$5.05
24h Volume:
33,281
Relative Volume:
0.66
Market Cap:
$32.22M
Revenue:
$500.00K
Net Income/Loss:
$-7.88M
P/E Ratio:
-3.0106
EPS:
-1.694
Net Cash Flow:
$-5.49M
1W Performance:
+18.33%
1M Performance:
+31.61%
6M Performance:
-56.52%
1Y Performance:
+97.67%
1-Day Range:
$4.9124
$5.23
1-Week Range:
$4.3842
$5.88
52-Week Range:
$2.15
$36.00
Exicure Inc Stock (XCUR) Company Profile
Name
Exicure Inc
Sector
Industry
Phone
847-673-1707
Address
2430 N. HALSTED ST., CHICAGO, IL
Compare XCUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
4.07 | 5.67B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.22 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.13 | 109.81M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.195 | 429.79M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.08 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-18-20 | Initiated | BMO Capital Markets | Outperform |
| Nov-20-19 | Initiated | Guggenheim | Buy |
Exicure Inc Stock (XCUR) Latest News
What margin trends mean for Exicure Inc. stockWeekly Profit Recap & Smart Allocation Stock Tips - newser.com
Can Exicure Inc. (2H0) stock attract analyst upgradesQuarterly Market Review & Stepwise Trade Execution Plans - newser.com
Volume spikes in Exicure Inc. stock – what they mean2025 Historical Comparison & Momentum Based Trading Signals - newser.com
Building trade automation scripts for Exicure Inc.July 2025 Closing Moves & Safe Capital Growth Stock Tips - newser.com
Will Exicure Inc. bounce back from current supportWeekly Profit Recap & Daily Oversold Stock Bounce Ideas - newser.com
Exicure’s (XCUR) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World
Should you hold or exit Exicure Inc. now2025 Volume Leaders & Advanced Swing Trade Entry Alerts - newser.com
Is Exicure Inc. (2H0) stock a safe buy pre earningsJuly 2025 Catalysts & Risk Controlled Stock Pick Alerts - newser.com
How analysts revise price targets for Exicure Inc. (2H0) stockJuly 2025 Final Week & Risk Managed Investment Signals - newser.com
Will Exicure Inc. stock reach Wall Street targets2025 Dividend Review & Verified Entry Point Detection - newser.com
Chart overlay techniques for tracking Exicure Inc.2025 Bull vs Bear & AI Forecasted Stock Moves - newser.com
Exicure’s burixafor nears phase 2 data readout in multiple myeloma By Investing.com - Investing.com Nigeria
Exicure Highlights Recent Achievements and Near-Term Strategic Priorities - MarketScreener
Will breakout in Exicure Inc. lead to full recoveryPortfolio Update Summary & AI Based Buy and Sell Signals - newser.com
Exicure (XCUR) Progresses with Promising Results in Phase 2 Buri - GuruFocus
Exicure’s burixafor nears phase 2 data readout in multiple myeloma - Investing.com
Exicure Inc 2H0 Stock Analysis and ForecastTake Profit Strategies & Free Tremendous Portfolio Expansion - earlytimes.in
Exicure Reports Progress in Burixafor (GPC-100) Phase 2 Trial for Multiple Myeloma and Plans Expansion into Sickle Cell Disease and AML with New Leadership Appointments - Quiver Quantitative
Exicure Highlights Recent Achievements and Near-term Strategic Priorities - The Manila Times
Burixafor Phase 2 shows promising interim mobilization results; topline readout due in - Stock Titan
Is Exicure Inc. (2H0) stock a defensive play amid uncertaintyMarket Risk Summary & Verified Swing Trading Watchlist - newser.com
Can technical indicators confirm Exicure Inc.’s reversalWeekly Investment Recap & Fast Exit and Entry Strategy Plans - newser.com
Using flow based indicators on Exicure Inc.July 2025 Opening Moves & Fast Entry and Exit Trade Plans - newser.com
Will Exicure Inc. (2H0) stock benefit from sector leadershipEntry Point & Stock Market Timing Techniques - newser.com
Why Exicure Inc. (2H0) stock appeals to dividend investorsWeekly Investment Summary & Daily Volume Surge Trade Alerts - newser.com
Is Exicure Inc. (2H0) stock a buy before earnings resultsWeekly Trade Summary & Real-Time Buy Signal Notifications - newser.com
Risk vs reward if holding onto Exicure Inc.Weekly Market Summary & Reliable Intraday Trade Alerts - newser.com
Is Exicure Inc. (2H0) stock a fit for income portfoliosMarket Activity Recap & Community Verified Watchlist Alerts - newser.com
Developing predictive dashboards with Exicure Inc. dataEarnings Beat & Technical Entry and Exit Alerts - newser.com
Is Exicure Inc a good long term investmentBullish Engulfing Patterns & See Risk Factors Before Making Any Move - earlytimes.in
Exicure Inc Stock (XCUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):